Cho, Byoung Chul http://orcid.org/0000-0002-5562-270X
Braña, Irene
Cirauqui, Beatriz
Aksoy, Sercan
Couture, Felix
Hong, Ruey-Long
Miller, Wilson H. Jr
Chaves-Conde, Manuel
Teixeira, Margarida
Leopold, Lance
Munteanu, Mihaela
Ge, Joy Yang
Swaby, Ramona F.
Hughes, Brett G. M.
Funding for this research was provided by:
Merck Sharp and Dohme
Incyte
Article History
Received: 4 August 2022
Accepted: 17 August 2023
First Online: 25 July 2024
Declarations
:
: The study and protocol were approved by the Institutional Review Board or ethics committee at each site and the study was conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki. All patients provided written informed consent to participate.
: Not applicable.
: BCC reports grants from Novartis, Bayer, AstraZeneca, MOGAM Institute, Dong-A ST, Champions Oncology, Janssen, Yuhan, Ono, Dizal Pharma, AbbVie, Medpacto, GIInnovation, Eli Lilly, Blueprint Medicines, Interpark Bio Convergence Corp, and Merck Sharp & LLC, a subsidiary of Merck & Co, Rahway, NJ, USA (MSD); personal fees for consulting or advisory roles from Novartis, AstraZeneca, Boehringer-Ingelheim, Roche, Bristol Myers Squibb, Ono, Yuhan, Pfizer, Eli Lilly, Janssen, Takeda, MSD, Medpacto, and Blueprint Medicines, KANAPH Therapeutic Inc, Bridgebio Therapeutics, Cyrus Therapeutics, Guardant Health, and Oscotec Inc.; stock ownership in TheraCanVac Inc, Gencurix Inc, Bridgebio Therapeutics, KANAPH Therapeutic Inc, Cyrus Therapeutics, and Interpark Bio Convergence Corp; board of director roles at Gencurix Inc. and Interpark Bio Convergence Corp.; royalties from Champions Oncology; and being a founder at DAAN Biotherapeutics outside the submitted work.IB reports grants and personal fees from MSD; and grants from Incyte during the conduct of the study; grants and personal fees from Orion Pharma, Merck Serono, Bristol Myers Squibb, and AstraZeneca; grants from Celgene, GlaxoSmithKline, Janssen Oncology, Kura, Regeneron, Novartis, Shattuck Labs, Boehringer Ingelheim, Seattle Genetics, Gliknik, and ISA Pharmaceuticals; and personal fees from Achilles Therapeutics, Cancer Expert Now, and eTheRNA immunotherapies outside the submitted work.BC reports grants from Bristol Myers Squibb, Roche, Merck, and MSD outside the submitted work.SA reports honoraria from Roche, Novartis, Astellas, Pfizer, and Abdi Ibrahim Pharmaceuticals; and advisory board fees from Roche, Novartis, Eli Lilly, Abdi Ibrahim Pharmaceuticals, Bristol-Myers Squibb, and MSD outside the submitted work.RLH reports grants from MSD outside the submitted work.WHM reports personal fees from Merck, Bristol Myers Squibb, Roche, Novartis, Amgen, and GlaxoSmithKline outside the submitted work.MCC, FC, and MT have nothing to disclose.LL and MM report employment at Incyte.JYG reports employment at Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and owns stock in Merck & Co., Inc., Rahway, NJ, USA.RFS reports employment at Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.BGMH reports grants from MSD during the conduct of the study; advisory board fees from MSD, Bristol Myers Squibb, Roche, Pfizer, Eisai, Takeda, and Astra Zeneca; and grants from Amgen outside the submitted work.